Kitov Pharmaceuticals’ phase III trial of KIT-302 meets primary efficacy endpoint
Data from the trial further revealed that KIT-302 was more efficacious at reducing hypertension than the widely used hypertension drug amlodipine besylate. Kitov plans to file its New